Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2009

Conditions
Plaque-type Psoriasis
Interventions
DRUG

COL-121

75 µg/g COL-121 Ointment

DRUG

50 µg/g Calcipotriene Ointment

50 µg/g Calcipotriene Ointment

DRUG

Placebo

Placebo

DRUG

COL-121

150 µg/g COL-121 Ointment

DRUG

COL-121

300 µg/g COL-121 Ointment

Trial Locations (20)

19034

Philadelphia Institute of Dermatology, Flourtown

24501

The Education & Research Foundation, Inc., Lynchburg

30263

MedaPhase, Inc., Newnan

33144

International Dermatology Research, Inc., Miami

40202

Dermatology Specialists, Louisville

48038

Michigan Center for Skin Care Research, Clinton Township

48088

Grekin Skin Institute, Warren

78258

Dermatology Associates of San Antonio, San Antonio

78759

DermResearch, Inc., Austin

80209

Cherry Creek Research, Inc., Denver

80501

Longmont Medical Research Network, Longmont

84124

Dermatology Research Center, Salt Lake City

87106

Academic Dermatology Associates, Albuquerque

90045

Dermatology Research Associates, Los Angeles

92083

Dermatology Specialists, Inc., Vista

92117

Skin Surgery Medical Group, Inc., San Diego

94538

East Bay Dermatology Medical Group, Fremont

97210

Northwest Cutaneous Research Specialists, Portland

99204

Premier Clinical Research, Spokane

06511

The Savin Center, PC, New Haven

Sponsors
All Listed Sponsors
lead

Deltanoid Pharmaceuticals

INDUSTRY